Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
P/B ratio for Crinetics Pharmaceuticals, Inc. (CRNX)
P/B ratio as of 2023: 3.83
According to Crinetics Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.83. At the end of 2022 the company had a P/B ratio of -2.17.
P/B ratio history for Crinetics Pharmaceuticals, Inc. from 2016 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.83 |
| 2022 | -2.17 |
| 2021 | -3.97 |
| 2020 | -2.56 |
| 2019 | -6.47 |
| 2018 | -8.39 |
| 2017 | -22.64 |
| 2016 | -54.83 |